S
ince the Food and Drug Administration approved intervertebral fusion cages in 1996, 1 the number of fusion surgeries in the United States has increased dramatically. 2, 3 Part of the growth is owing to the fact that studies show most patients with an indication of spinal stenosis realize pain relief and functional improvement with this procedure. [4] [5] [6] In addition, some part of the growth is owing to financial incentives that reward providers significantly more for performing these surgeries over other lessinvasive procedures such as lumbar decompression. 7, 8 Regardless of the reason, during fiscal year (FY)-2013, the Medicare program reimbursed hospitals over $3.6 billion for spinal fusion surgery, making total spending on spinal fusion surgery one of the three highest admission outlays in the Medicare program; along with total knee arthroplasty and congestive heart failure. 9 A number of articles have reported on mortality and selected adverse events associated with patients undergoing spinal fusion surgery [10] [11] [12] [13] [14] and other studies have examined length of stay 8, 15 and unplanned readmission after spinal surgery. 16, 17 However, only a few of these studies used a national sample of spinal surgery patients in the United States 8, 11, [13] [14] [15] or attempted to estimate the economic burden of treating patients experiencing adverse events during a hospitalization associated with a lumbar spinal fusion surgery. The unique primary objective of this analysis is to estimate the incremental hospital resources consumed (dollar value of direct medical care provided and length of stay [LOS] ) of treating acute adverse events experienced by Medicare Beneficiary (MB) who underwent primary 2 or 3 vertebra lumbar spinal fusion (2-3VLSF) surgery during FY-2013.
METHODS Data Source
The Medicare Provider Analysis and Review (MedPAR) file for FY-2013 (October 1, 2012 through September 30, 2013) was the data source for this retrospective analysis. The MedPAR file is an administrative database that is maintained by the Centers for Medicare and Medicaid Services and contains all claims submitted by hospitals for services provided to MBs. Information for each hospitalization includes patient information on age, sex, race, up to 25 diagnosis codes, an indication flag identifying whether or not each diagnosis code was present on admission, up to 25 procedure codes, length of hospital stay in days, discharge status, and total charges.
Study Population-Inclusion/Exclusion
The population in this study consisted of all US hospitalizations in which a MB underwent a 2-3VLSF during FY-2013. There were a total of 84,730 hospital admissions for MB with an International Classification of Diseases 9-Clinical Modification (ICD-9-CM) procedure code of 81.06, 81.07, or 81.08 indicating that the MB underwent a lumbar fusion procedure (anterior technique, lateral transverse process technique, or posterior technique) and that the fusion procedure only included 2 or 3 vertebra (ICD-9-CM procedure code of 81.62), without having any refusion ICD-9-CM procedure codes (81.31, 81.32, 81.33, 81.34, 81.35, 81.36, 81.37, or 81.38) during their hospitalization. Hospitalization was excluded for the following reasons: 504 hospitalizations because of low estimated use of hospital resources (total estimated cost below $4000); 570 hospitalizations because the MBs also underwent another fusion procedure: 84 cervical fusion procedures; 428 dorsal fusion procedures; and 58 unspecified fusion procedures. Because four hospitalizations were excluded for both criteria, the final study dataset consists of 83,658 hospital admissions in 3162 US hospitals.
Definitions of Adverse Events
Nine administratively defined adverse events of interest were defined for this study: in-hospital death; mechanical complications; dural tear; cardiac event (acute myocardial infarction, ventricular tachycardia or fibrillation, or cardiac arrest); respiratory complication (postoperative adult respiratory distress syndrome, pneumonia, or ventilator associated pneumonia); infection (infection caused by a device or implant, infection caused by urinary catheter, postoperative infection, or sepsis); transfusion (transfusion following hemorrhage or postoperative shock; transfusion without hemorrhage or postoperative shock); VTE (pulmonary embolism or venous thromboembolism). Appendix A, http://links.lww.com/BRS/B149 lists the ICD-9-CM procedure and diagnosis codes used to identify each adverse event. All adverse events reported in this study occurred during the operative hospitalization.
Demographic, Comorbidity, and Procedure Controls
Demographic controls included: age group (under 65, 65-69, 70-74, 75-79, and 80 plus), sex (men or women), and race (white, black, hispanic, or all other). Comorbidity controls, identified using ICD-9-CM diagnosis codes, included: obesity, body mass index greater than 30, diabetes mellitus, current smoker, history of smoker, congestive heart failure, previous myocardial infarction, hypertension, malnutrition, rheumatoid arthritis, osteoporosis, coagulopathies, anemia present on admission, chronic obstructive pulmonary disease, chronic kidney disease, previous cevebral vascular accident, previous cardiac revascularization procedure, previous VTE, long-term use of aspirin, long-term use of anticoagulation, long-term use of antiplatelet, long-term use of NSAIDs, and long-term use of steroids, lumbar fracture present on admission, bone infection present on admission, lumbar spondylosis present on admission, malignant tumors present on admission, benign tumors present on admission, spondylolisthesis, and degenerative disc disease. Procedure controls included the count of procedures (insertion of interbody spinal fusion device, insertion of recombinant bone morphogenetic protein, insertion of bone spacer, or any synchronous excision of locally harvested bone graft) performed during the lumbar spinal fusion and the procedure techniques (anterior only, posterior only, posterior interbody only, anterior and posterior, anterior and posterior interbody, posterior and posterior interbody, and all three techniques).
Hospital Resource Utilization
This study examined two alternative measures of the hospital resources consumed in treating the selected complication of interest: total hospital cost and LOS. This study only includes resources consumed during the 2-3VLSF hospital admission and does not include any physician resources or resources consumed post discharge in other facilities. Hospital resource costs (2013 US dollars) were estimated by multiplying total hospital charges by the appropriate hospital's overall cost-to-charge ratio, obtained from the FY-2013 Medicare Cost Report. This method of estimating total hospital cost has been used previously in the literature.
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Statistical Analysis
Univariate differences in baseline demographic data and comorbidities between patients who experienced any adverse event and those who did not were assessed with x 2 analysis or Fisher exact test for discrete variables and Student t test for continuous variables. Observed event rates are reported as the proportion of hospitalizations with a selected complication out of all study hospitalizations. Mean hospital cost and mean hospital LOS for all patients experiencing selected adverse events are presented as mean AE SD. All multivariate regression models were estimated using the linear forms of the estimated resource equation. In this study, differences between study groups were considered statistically different if the P value was less than or equal to 0.01. All analyses were performed with SAS 9.3 (SAS Institute, Cary, NC).
Strategy for Estimating Incremental Resource Use
We report the observed, average incremental resources of treating each adverse event as the difference between the average hospital resources consumed by all MBs who experience that specific adverse event versus either: those MBs who did not experience that specific adverse event; or only those MBs who did not experience any adverse event during their hospitalization. Incremental adjusted resources consumed by MBs experiencing a specific study adverse event were estimated using a dichotomous variable that was set equal to 1 if the patient experienced the adverse event of interest and set to 0 for all MBs in the sample not experiencing any of the other study adverse events. These estimation approaches are similar to those used to estimate the incremental cost of treating adverse events associated with total knee arthroplasty 16 . Table 1 presents observed differences in baseline demographic and clinical characteristics for all MBs and by whether or not the MBs experienced one or more of the study's adverse events. In general, patients who experienced adverse events were more likely to be older than 75 years, female, and nonwhite. The three most common comorbidities among MBs undergoing lumbar spinal fusion were hypertension (68.6%), diabetes mellitus (25.6%), and spondylolisthesis (16.20%). A comparison of the two study populations indicates that there were no statistical differences between the two study groups for five of the comorbid conditions. For all but two of the other 26 comorbid conditions, MBs experiencing at least one of adverse events were significantly (P < 0.01) more likely to have the selected comorbidities than MBs not experiencing any adverse events. The exceptions were MBs who were current smokers or had degenerative disc disease. Finally, Table 1 indicates that MB who experienced one or more of the study adverse events had a significantly higher post-discharge mortality rate in the first 90 days compared to MB not experiencing an adverse event. Table 2 indicates that a total of 17.73% of all MBs undergoing a 2-3VLSF experienced one or more of the prespecified adverse events; 15.35% of MBs (12,841) experienced only one of the study adverse events. The three most common adverse events among MBs were transfusion (11.3%), dural tear (4.64%), and renal complication (2.11%). A total of 120 MBs (0.14%) undergoing 2-3VLSF died during that hospitalization. Table 2 also presents the percentage of the study population and patient count for all the individuals who experienced any of the adverse events that were included in the combined study adverse events of cardiac, renal, respiratory, infection, transfusion, and VTE. Table 4 presents estimates of the risk-adjusted incremental hospital cost and LOS associated with treating patients who developed each of the study adverse events of interest. The risk-adjusted estimated incremental cost of each adverse event exceeded $10,000 and the risk-adjusted estimated incremental LOS exceeded 2.0 days for all study adverse events, except for MBs receiving transfusion and dural tear. The three adverse events that resulted in the largest riskadjusted incremental cost and incremental LOS were infection, in-hospital death, and VTE. 
RESULTS

DISCUSSION
Several important findings emerge from this analysis. First, the overall rate of administratively defined adverse events among MBs undergoing 2-3VLSF was 17.73% (14,831 hospitalizations). Second, the three most common adverse events experienced by MBs during 2-3 VLSF were transfusion, dural tear, and renal complication. However, four adverse events (in-hospital mortality, mechanical complications, VTE, and cardiac adverse event) occurred in less than 0.5% of all MB's lumbar spinal fusions. Third, the adverse event rates reported here appear to be lower than the similar adverse event rates reported in other studies. [10] [11] [12] [13] [14] However, it is nearly impossible to compare our rates directly with the rates reported in other studies because of difference in patient population and range and types of fusion surgery included in those studies. Furthermore, our adverse event rates only include events that occurred during the initial procedural hospitalization with the exception of death. Fourth, our study confirms that among MBs undergoing 2-3VLSF, 120 (0.14%) died during their initial hospitalization associated with this procedure and an additional 586 (0.70%) died within the first 90 days post-discharge. This analysis provides a set of nationally representative cost benchmarks for the mean incremental hospital resources consumed while treating each of the adverse events identified. First, MBs who experienced at least one study adverse event consumed significantly more incremental hospital resources (observed cost $8911 and observed LOS 2.4 days) than did MBs who did not experience any complications. It should be noted that the observed incremental LOS associated with adverse events found in this study is consistent with the 2.2 incremental LOS for patients experiencing postoperative complications in the literature.
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Finally, after controlling for patient risk factors, the estimated incremental cost of treating the study adverse exceeded $20,000 and the incremental LOS exceed 4.8 days for all but three of the adverse events studied: dural tear, transfusion, and renal complication. Estimates of the total incremental resource cost of treating selected complications can be derived by combining the incremental hospital resource cost (Table 4) with the number of MBs experiencing the adverse event (Table 2) . For example, hospitals used an additional $81.6 million of resources in treating MBs who experienced transfusions: $17.8 million in treating respiratory complication and $17.7 million treating infections. This suggests significant opportunity for reducing total hospital resources treating adverse events if quality improvement efforts reduce inpatient complication rates.
There are several limitations that warrant discussion. First, this analysis applies only to MB. It should not be assumed that our findings on the incremental cost of treating adverse events can be extrapolated to other patient groups, especially younger patients. A second limitation is that the identification of MBs undergoing 2-3VLSF is dependent on ICD-9-CM procedures codes and our dataset does not allow us to evaluate whether surgery was the most appropriate treatment option. A related limitation is that the identification of study adverse events was dependent on ICD-9-CM coding. This limitation is mitigated by the fact that the MedPAR file contains present on admission flags to differentiate between diagnoses, which existed on admission from those that occurred during or after the procedure. A third limitation is the potential for variation in coding philosophy among hospitals toward documenting comorbidities. It should be noted, however, if hospitals use more aggressive coding on patients that experienced an adverse event, then our risk-adjusted regression cost estimates most likely underestimate the true incremental cost of an adverse event because the model would attribute more of the cost variation to the increased number of comorbid conditions. A fourth limitation is that our dataset does not allow us to link the initial hospitalization with future hospitalizations so we are only able to report adverse events that occurred during the initial hospitalization. A final limitation is that hospital costs were estimated from billed charges and may not measure true resources consumed. Nevertheless, it is reassuring that a similar pattern of incremental resource utilization emerges from our analysis of LOS data.
CONCLUSION
In FY-2013, approximately one-fifth of MBs undergoing 2-3VLSF experienced one or more of the prespecified adverse events. The risk-adjusted incremental hospital resources consumed in treating all but three of the adverse events exceeded $20,000 per episode. Surgeons and hospitals are increasingly at financial risk for the incremental resources consumed in treating patients experiencing adverse events as third-party payers' are implementing single bundled payments for acute surgical episodes, and/or creating payment exclusions for specific hospital acquired conditions (such as surgical site , diabetes mellitus, current smoker, history of smoking, congestive heart failure, chronic ischemic heart disease, previous myocardial infarction, hypertension, malnutrition, rheumatoid arthritis, osteoporosis, coagulopathies, anemia POA, chronic obstructive pulmonary disease, chronic kidney disease, previous cevebral vascular accident, previous revascularization procedure, previous VTE, long-term use of aspirin, long-term use of anticoagulation, long-term use of antiplatelet, long-term use of nonsteroidal anti-inflammatory drugs, long-term use of steroids, any lumbar fracture POA, infection of the bone POA, any lumbar spondylosis POA, malignant tumors POA, and benign tumors POA, spondylolisthesis, degenerative disc disease), the count of the number of the following procedures (insertion of interbody spinal fusion device, insertion of recombinant bone morphogenetic protein, insertion of bone spacer, or any synchronous excision of locally harvested bone graft) performed, the specific techniques (anterior only, posterior interbody only, anterior and posterior, anterior and posterior interbody, posterior and posterior interbody, and all three techniques), and the specific complication of interest. LOS indicates length of stay; POA, present on admission; VTE, venous thromboembolism. All estimated incremental cost or LOS values are significantly (P < .001) different from zero.
infections). In these payment models, the treatment of adverse events will increase costs without any offsetting increase in reimbursement. The results of this study provide institutions with critical cost data related to these common complications. Furthermore, it suggests that investment in activities that have been shown to reduce specific adverse events is warranted, and this project may allow health systems to prioritize performance improvement areas.
Key Points
The overall rate of administratively defined adverse events for the 83,658 MBs undergoing 2 -3VLSF was 17.73% (14,831 Medicare hospitalizations). The three most common adverse event experience by MBs during lumbar spinal fusion were transfusion (11.26%, 9421 beneficiaries), dural tear (4.64%, 3882 beneficiaries), and renal complication (2.11%, 1768 beneficiaries). The 17.73% of MBs who experienced at least one study adverse event consumed significantly more hospital resources (observed incremental cost $8911 per hospitalization) and had a longer observed LOS (incremental LOS 2.4 days) than did MBs who did not experience any complications during their lumbar spinal fusion. After controlling for patient's demographic characte ristics and comorbiditie s, the incremental cost of treating the study adverse events exceeded $20,000 and the incremental LOS required to treat these complications exceeded 4.8 days for all but three of the adverse events studied: dural tear, transfusion, and renal complication.
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